Treatment Outcomes in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer Patients with and without Progression after Completion of Reimbursed Cyclin-dependent Kinase 4/6 Inhibitors in Taiwan: A Single-institution Experience

Background: Combining cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) with endocrine therapy is the standard first-line treatment for metastatic hormone receptor (HR)-positive, HER2-negative breast cancer. In Taiwan, it is estimated that nearly half of the patients completing 2 years of CDK4/6i tr...

Descrición completa

Detalles Bibliográficos

Principais autores:	Yi-Hsuan Hsu, Po-Shen Yang, Yuan-Ching Chang, Hung-Bun Lam, Fang Lee, Chia-Yen Hung, Johnson Lin, Nei-Wen Su, Yi-Hao Chiang, Huan-Chao Lin, Wen-Ching Ko, Chung-Hsin Tsai, Ying-Wen Su
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wolters Kluwer Medknow Publications 2026-01-01
Series:	Journal of Cancer Research and Practice
Assuntos:	cyclin-dependent kinase 4/6 inhibitor overall survival progression-free survival real-world data taiwan national health insurance reimbursement
Acceso en liña:	https://journals.lww.com/10.4103/ejcrp.eJCRP-D-25-00018
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!